These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22826520)

  • 41. Intranasal midazolam: a comparison of two delivery devices in human volunteers.
    Dale O; Nilsen T; Loftsson T; Hjorth Tønnesen H; Klepstad P; Kaasa S; Holand T; Djupesland PG
    J Pharm Pharmacol; 2006 Oct; 58(10):1311-8. PubMed ID: 17034653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.
    Samuelsson K; Pickup K; Sarda S; Swales JG; Morikawa Y; Schulz-Utermoehl T; Hutchison M; Wilson ID
    Xenobiotica; 2012 Nov; 42(11):1128-37. PubMed ID: 22642803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology of midazolam in infants and children.
    Blumer JL
    Clin Pharmacokinet; 1998 Jul; 35(1):37-47. PubMed ID: 9673833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction.
    Platten HP; Schweizer E; Dilger K; Mikus G; Klotz U
    Clin Pharmacol Ther; 1998 May; 63(5):552-60. PubMed ID: 9630828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
    Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
    Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas.
    Aarnes TK; Fry PR; Hubbell JA; Bednarski RM; Lerche P; Chen W; Bei D; Liu Z; Lakritz J
    Am J Vet Res; 2013 Feb; 74(2):294-9. PubMed ID: 23363357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics.
    Hilbert JM; Battista D
    J Clin Psychiatry; 1991 Sep; 52 Suppl():21-6. PubMed ID: 1680120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
    Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
    Eur J Clin Pharmacol; 2006 Mar; 62(3):185-94. PubMed ID: 16425056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.
    Zimmermann T; Yeates RA; Laufen H; Scharpf F; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1996 Feb; 46(2):213-7. PubMed ID: 8720318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concentrations of remifentanil, propofol, fentanyl, and midazolam during rewarming from therapeutic hypothermia.
    Bjelland TW; Klepstad P; Haugen BO; Nilsen T; Salvesen O; Dale O
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):709-15. PubMed ID: 24611449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Midazolam for continuous sedation in Japanese critical care patients: phase II study.
    Kinoshita K; Sakurai A; Mera K; Shirai K; Hone J; Moriya T; Okuno K; Noda E; Yoshida S; Kaburagi M; Kashiwa M; Imai Y; Tanjoh K; Hayashi N
    J Int Med Res; 2001; 29(4):342-8. PubMed ID: 11675908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
    Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Midazolam--how safe is it in sedation of newborn?].
    Gulczyńska E
    Pol Merkur Lekarski; 2005 Dec; 19(114):816-8. PubMed ID: 16521431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioavailability of a novel midazolam gel after intranasal administration in dogs.
    Eagleson JS; Platt SR; Strong DL; Kent M; Freeman AC; Nghiem PP; Zheng B; White CA
    Am J Vet Res; 2012 Apr; 73(4):539-45. PubMed ID: 22452501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.
    Gudmundsdottir H; Sigurjonsdottir JF; Masson M; Fjalldal O; Stefansson E; Loftsson T
    Pharmazie; 2001 Dec; 56(12):963-6. PubMed ID: 11802661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
    Urva S; Bouillaud E; Delaney R; Jappe A; Cheung W
    J Clin Pharmacol; 2013 Apr; 53(4):444-50. PubMed ID: 23426978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determinants of pharmacologic effects and toxicity of benzodiazepine hypnotics: role of lipophilicity and plasma elimination rates.
    Arnold J
    J Clin Psychiatry; 1991 Sep; 52 Suppl():11-4. PubMed ID: 1654317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers.
    Braun IM; Tavares H; de Nucci G; Bernik M
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):723-8. PubMed ID: 18620849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Important role of population pharmacokinetic/pharmacodynamic modeling in pediatric therapeutics.
    Vinks AA
    J Pediatr; 2011 Sep; 159(3):361-3. PubMed ID: 21764403
    [No Abstract]   [Full Text] [Related]  

  • 60. What May Be the First Phase 4 Experience with BYFAVO (Remimazolam).
    Henson KS; Thompson KJ
    AANA J; 2021 Apr; 89(2):101-102. PubMed ID: 33832568
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.